Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial

Russell, N. H., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M. F., Cahalin, P., Dennis, M., Friis, L., Grech, A., Milligan, D., Clark, R. and Burnett, A. K. 2016. Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial. British Journal of Haematology 173 (S1) , p. 9.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	Special Issue: Abstracts of the XXXVI World Congress of the International Society of Hematology Hosted by the British Society for Haematology, 18–21 April 2016, Glasgow, UK
Publisher:	Wiley-Blackwell
ISSN:	0007-1048
Last Modified:	02 Nov 2022 10:22
URI:	https://orca.cardiff.ac.uk/id/eprint/98413

Actions (repository staff only)

Edit Item